Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Pollard

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Psychiatric Services (Washington, D.C.)|November 3, 2009
Public-academic partnerships: early intervention for psychotic disorders in a community mental health centerVinod H Srihari, Nicholas J K Breitborde, Jessica Pollard, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2015
First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled TrialVinod H Srihari, Cenk Tek, Suat Kucukgoncu, et al.
Clinical Case Reports|November 29, 2023
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantationFranziska Wachter, Yana Pikman, Jacob Bledsoe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology GroupTodd M Cooper, Michael J Absalon, Todd A Alonzo, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
JCO Precision Oncology|September 11, 2020
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupLata Chauhan, Miyoung Shin, Yi-Cheng Wang, et al.
Pediatric Blood & Cancer|August 12, 2020
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia ConsortiumTaizo A Nakano, Bonnie W Lau, Kathryn E Dickerson, et al.
Pediatric Blood & Cancer|April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Psychiatric Services (Washington, D.C.)|November 3, 2009
Public-academic partnerships: early intervention for psychotic disorders in a community mental health centerVinod H Srihari, Nicholas J K Breitborde, Jessica Pollard, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2015
First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled TrialVinod H Srihari, Cenk Tek, Suat Kucukgoncu, et al.
Clinical Case Reports|November 29, 2023
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantationFranziska Wachter, Yana Pikman, Jacob Bledsoe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology GroupTodd M Cooper, Michael J Absalon, Todd A Alonzo, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
JCO Precision Oncology|September 11, 2020
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupLata Chauhan, Miyoung Shin, Yi-Cheng Wang, et al.
Pediatric Blood & Cancer|August 12, 2020
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia ConsortiumTaizo A Nakano, Bonnie W Lau, Kathryn E Dickerson, et al.
Pediatric Blood & Cancer|April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
Pageof 3